Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 18/20 | 0.66 |
| ▸ | MMP9 | P14780 | 18/20 | 0.66 |
| ▸ | MMP13 | P45452 | 3/20 | 0.42 |
| ▸ | MMP8 | P22894 | 3/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4662848 | 0.83 | MMP2 (0.63) | MMP2MMP9ADAM17 | |
| SCHEMBL4664602 | 0.83 | MMP2 (0.72) | MMP2MMP9MMP13MMP8ADAM17 | |
| SCHEMBL4664591 | 0.81 | MMP2 (0.69) | MMP2MMP9MMP13MMP8ADAM17 | |
| SCHEMBL4663101 | 0.80 | MMP2 (0.59) | MMP2MMP9MMP13MMP8ADAM17 | |
| SCHEMBL6447921 | 0.79 | MMP2 (0.70) | MMP2MMP9MMP13MMP8ADAM17 | |
| SCHEMBL726759 | 0.79 | MMP2 (1.00) | MMP2MMP9MMP13ADAM17 | |
| SCHEMBL8471189 | 0.79 | MMP2 (0.80) | MMP2MMP9MMP13MMP8ADAM17 | |
| SCHEMBL4663111 | 0.78 | MMP2 (0.57) | MMP2MMP9MMP13MMP8 | |
| SCHEMBL7474147 | 0.78 | MMP2 (0.64) | MMP2MMP9MMP13MMP8MMP3 | |
| SCHEMBL4663104 | 0.77 | MMP2 (0.64) | MMP2MMP9MMP13MMP8ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096897-A1 | 5-(1,1'Biphenyl)-4-Yl-5-(4-(4-Aminoacylphenyl)-Piperazin)-1-Yl-Pyrimidine-2,4,6,-Trione Derivatives, As Inhibitors Of Zinc Metallondopeptidases, Their Preparation And Use | UNIVERSITE DE LIEGE (BE) | 2008-04-24 | — | — | US | claimed |
| EP-1784397-A1 | 5-(1,1'-BIPHENYL)-4-YL-5-(4-(4-AMINOACYLPHENYL)-PIPERAZIN)-1-YL-PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, AS INHIBITORS OF ZINC METALLONDOPEPTIDASES, THEIR PREPARATION AND USE | Université de Liège (BE) | 2007-05-16 | — | — | EP | claimed |
| EP-1632489-A1 | 5-(1,1'-Biphenyl)-4-yl-5-(4-(4-aminoacylphenyl)-piperazin)-1-yl-pyrimidine-2,4,6-trione derivatives, as inhibitors of zinc metallondopeptidases, their preparation and use. | University of Liege (BE) | 2006-03-08 | — | — | EP | claimed |
| WO-2006021533-A1 | 5-(1,1'-BIPHENYL)-4-YL-5-(4-(4-AMINOACYLPHENYL)-PIPERAZIN)-1-YL-PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, AS INHIBITORS OF ZINC METALLONDOPEPTIDASES, THEIR PREPARATION AND USE | UNIVERSITE DE LIEGE (BE) | 2006-03-02 | — | — | WO | claimed |
| US-20080096897-A1 | 5-(1,1'Biphenyl)-4-Yl-5-(4-(4-Aminoacylphenyl)-Piperazin)-1-Yl-Pyrimidine-2,4,6,-Trione Derivatives, As Inhibitors Of Zinc Metallondopeptidases, Their Preparation And Use | UNIVERSITE DE LIEGE (BE) | 2008-04-24 | — | — | US | disclosed |
| EP-1632489-A1 | 5-(1,1'-Biphenyl)-4-yl-5-(4-(4-aminoacylphenyl)-piperazin)-1-yl-pyrimidine-2,4,6-trione derivatives, as inhibitors of zinc metallondopeptidases, their preparation and use. | University of Liege (BE) | 2006-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096897-A1 | 5-(1,1'Biphenyl)-4-Yl-5-(4-(4-Aminoacylphenyl)-Piperazin)-1-Yl-Pyrimidine-2,4,6,-Trione Derivatives, As Inhibitors Of Zinc Metallondopeptidases, Their Preparation And Use | CTRL, TPP1, SERPINB1 | MMP2 16/4885MMP9 54/4885MMP13 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.